News
BFRI
0.9350
-5.42%
-0.0536
Biofrontera GAAP EPS of -$0.41 misses by $0.33, revenue of $10.1M misses by $0.4M
Seeking Alpha · 23h ago
Biofrontera targets cash flow breakeven in 2026 while aiming for 80%-85% gross margin
Seeking Alpha · 1d ago
Transcript: Biofrontera Q1 2026 Earnings Conference Call
Benzinga · 1d ago
Biofrontera Q1 EPS $(0.41) Misses $(0.12) Estimate, Sales $10.084M Miss $10.250M Estimate
Benzinga · 1d ago
CORRECTED-Biofrontera Q1 revenue rises on higher Ameluz sales
Reuters · 1d ago
*Biofrontera 1Q Loss/Shr 41c >BFRI
Dow Jones · 1d ago
*Biofrontera 1Q Rev $10.1M >BFRI
Dow Jones · 1d ago
Earnings Scheduled For May 14, 2026
Benzinga · 1d ago
Weekly Report: what happened at BFRI last week (0504-0508)?
Weekly Report · 4d ago
Biofrontera schedules first-quarter results conference call
PUBT · 6d ago
Weekly Report: what happened at BFRI last week (0427-0501)?
Weekly Report · 05/04 10:37
Weekly Report: what happened at BFRI last week (0420-0424)?
Weekly Report · 04/27 10:41
Weekly Report: what happened at BFRI last week (0413-0417)?
Weekly Report · 04/20 10:36
Biofrontera FY25 operating loss narrows 35.4% to EUR 1 million; revenue rises to EUR 13.2 million
PUBT · 04/17 22:23
Biofrontera publishes 2025 annual report
PUBT · 04/17 21:23
Weekly Report: what happened at BFRI last week (0406-0410)?
Weekly Report · 04/13 10:41
Weekly Report: what happened at BFRI last week (0330-0403)?
Weekly Report · 04/06 10:41
Weekly Report: what happened at BFRI last week (0323-0327)?
Weekly Report · 03/30 10:42
Weekly Report: what happened at BFRI last week (0316-0320)?
Weekly Report · 03/23 10:37
Roth MKM Reaffirms Their Buy Rating on Biofrontera (BFRI)
TipRanks · 03/20 13:17
More
Webull provides a variety of real-time BFRI stock news. You can receive the latest news about Biofrontera Inc through multiple platforms. This information may help you make smarter investment decisions.
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.